Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
GlaxoSmithKline's office. Photo: Sven Hoppe/picture alliance via Getty Images
The results of home DNA testing company 23AndMe will be used by pharmaceutical giant GlaxoSmithKline to design new drugs, NBC News reports.
The details: 23AndMe users were allowed to opt out of research, NBC reports. The first goal is to design a new drug to treat Parkinson's disease by looking at a gene called LRRK2. 23AndMe CEO Anne Wojcicki said in a blog post about the companies' collaboration: "By working with GSK, we believe we will accelerate the development of breakthroughs."